JIANGSU | Jotup

Ostin Technology Group Co., Ltd. to Hold Annual General Meeting of Shareholders on September 28, 2023

Retrieved on:

Wednesday, August 30, 2023

Bank statement, Eastern Time Zone, Telephone, AND, Internet, Time in China, Annual report, Security (finance), Proxy

Shareholders of record at the close of business on August 18, 2023 are entitled to receive notice and vote at the annual meeting and any adjournment or postponement thereof.

Key Points:

Shareholders of record at the close of business on August 18, 2023 are entitled to receive notice and vote at the annual meeting and any adjournment or postponement thereof.
All shareholders are cordially invited to attend the meeting in person.
Whether or not you plan to attend the annual meeting, we encourage you to vote and submit your proxy by telephone, via the Internet or by mail.
In addition, the proxy statement, as well as our 2022 Annual Report, are available on our Internet website at http://ostin-technology.com/download-65-63-50.html .

Ostin Technology Group Plans to Launch New M4 and GT8-PRO Smartwatches Via Short-Video Platforms

Retrieved on:

Thursday, August 10, 2023

Tao, M4, GPS, Electronics, National Emergency Message, Mo Ostin, Research, United Nations Information Center Washington, App Store (iOS/iPadOS), US, WeChat, Health, Social media, Mobile phone, Video game, Alipay

These smartwatch products are expected to be officially available for purchase on Douyin (TikTok) platform in the third quarter this year.

Key Points:

These smartwatch products are expected to be officially available for purchase on Douyin (TikTok) platform in the third quarter this year.
The Company is also expected to market and sell its smartwatch products through other popular short-video platforms, including Kuaishou (Kwai) and WeChat Channel.
The Company aims to boost its sales through live streaming, fans communities and advertising on social media platforms.
The Company expects the two smartwatch products to have strong sales performance via these new media platforms in the first year after the launch.

Triastek Reports Positive FIH Results from Study of T21, a 3D Printed Oral Treatment for Moderate to Severe Ulcerative Colitis

Retrieved on:

Friday, July 21, 2023

Gastrointestinal tract, 3D, Medicine, Ulcerative colitis, Eli Lilly, Colon, Tablet, Boehringer Ingelheim, T21, UC, Patient, FIH, Merck, MED, Safety, Pharmaceutical industry

Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug’s release.

Key Points:

Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug’s release.
The administration of oral medication is generally regarded as the preferred method for patients with UC due to its safety, pain avoidance and patient compliance.
Triastek developed T21 in an effort to solve the problem of targeted and precise delivery of oral drugs to the gastrointestinal tract.
Triastek aims to develop partnerships with pharmaceutical companies to help it differentiate its products through the use of 3D printing of medicines.

Ostin Technology Group Secures Orders for Metro Projects in Beijing, Tianjin, and Nanjing of China

Retrieved on:

Monday, July 17, 2023

Tao, Metro, LC, PIS, LCD, Safety, Tunnel

These products are designed to offer metro passengers with convenient commuting experience while accommodating security needs for the Company’s customers.

Key Points:

These products are designed to offer metro passengers with convenient commuting experience while accommodating security needs for the Company’s customers.
The Company's metro platform display products also provide modular design and network operation features with extensive content publishing capabilities.
Mr. Tao Ling, Chairman and CEO of the Company commented: “We are honored to supply the Company’s metro platform display products to metro projects in Beijing, Tianjin, and Nanjing of China.
We commit to provide high-quality and long-term display solutions meeting the need of each city’s metro projects.

Guqin, the ninth episode of the "Jiangsu Culture" series micro-documentary released

Retrieved on:

Friday, July 14, 2023

Music, Ear, Poetry, Perception, Multimedia, Information, Literature, Nature, Temperament, Sound, Entertainment, Guqin

NANJING, China, July 14, 2023 /PRNewswire/ -- The ninth episode of the "Jiangsu Culture" series micro-documentary, produced by the Information Office of the Jiangsu Provincial People's Government, has been released.

Key Points:

NANJING, China, July 14, 2023 /PRNewswire/ -- The ninth episode of the "Jiangsu Culture" series micro-documentary, produced by the Information Office of the Jiangsu Provincial People's Government, has been released.
This episode focuses on the Guqin, which is considered the most representative solo instrument in China.
The documentary consists of three chapters: "Making Guqin", "Temperament", and "Aesthetic Conception", taking viewers to the heritage sites of the Guqin in Zhenjiang and Nantong.
It introduces the elegant and melodic tunes, the intricate and exquisite playing techniques, and the unique notation system of the Guqin art.

Shineco Enters into Cooperation Agreement with Kangling Medical to Develop New Medical Products Company

Retrieved on:

Wednesday, June 28, 2023

Agreement, Personal protective equipment, Culture, SISI, Research, Sale, Accounting, Patient, RMB, Pharmaceutical industry

BEIJING, June 28, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. (“Shineco Life Science”), signed a joint venture cooperation agreement (the “Agreement”) with Yangzhou Kangling Medical Co., Ltd. ("Kangling Medical"), to establish a joint venture company, Shangkang Life Science and Technology (Jiangsu) Co., Ltd (“Shangkang Life Science”).

Key Points:

BEIJING, June 28, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. (“Shineco Life Science”), signed a joint venture cooperation agreement (the “Agreement”) with Yangzhou Kangling Medical Co., Ltd. ("Kangling Medical"), to establish a joint venture company, Shangkang Life Science and Technology (Jiangsu) Co., Ltd (“Shangkang Life Science”).
The joint venture will be formed to improve the delivery of healthcare services and medical products throughout China.
Kangling Medical, formerly known as Jiangdu Medical Electronic Equipment Enterprise, was established in 1997 in Jiangsu Province, China, and the ‘Kangling’ brand is recognized in China for its premier medical products.
The cooperation between our two parties will expand our global sales channels and Shineco’s resources will vastly improve the research and development capabilities of Kangling Medical.”

"ESG Investment Pioneer City" Nanjing Expands Investment Network

Retrieved on:

Tuesday, June 20, 2023

NANJING, China, June 20, 2023 /PRNewswire/ -- Nanjing, the capital of China's Jiangsu province, is striving to become a pioneer city for ESG (Environment, Social, Governance) investment, with its network of like-minded enterprises continuing to expand.

Key Points:

NANJING, China, June 20, 2023 /PRNewswire/ -- Nanjing, the capital of China's Jiangsu province, is striving to become a pioneer city for ESG (Environment, Social, Governance) investment, with its network of like-minded enterprises continuing to expand.
Just four months after the inaugural salon, the "Nanjing Wuxiang ESG Sustainable Investment Salon" was held once again on June 18th to 19th.
A central achievement of this salon was the release and interpretation of the "Nanjing ESG Sustainable Investment Research Report" by JLL (Jones Lang LaSalle).
The Nanjing Municipal Investment Promotion Bureau proposed, building on the success of the first two Nanjing Wuxiang ESG Sustainable Investment Salon events, that the organizers leverage the strengths of its guests to continue expanding Nanjing's ESG investment network, gather more green development resources, and inject greater momentum into Nanjing's sustainable development.

"ESG Investment Pioneer City" Nanjing Expands Investment Network

Retrieved on:

Tuesday, June 20, 2023

NANJING, China, June 20, 2023 /PRNewswire/ -- Nanjing, the capital of China's Jiangsu province, is striving to become a pioneer city for ESG (Environment, Social, Governance) investment, with its network of like-minded enterprises continuing to expand.

Key Points:

NANJING, China, June 20, 2023 /PRNewswire/ -- Nanjing, the capital of China's Jiangsu province, is striving to become a pioneer city for ESG (Environment, Social, Governance) investment, with its network of like-minded enterprises continuing to expand.
Just four months after the inaugural salon, the "Nanjing Wuxiang ESG Sustainable Investment Salon" was held once again on June 18th to 19th.
A central achievement of this salon was the release and interpretation of the "Nanjing ESG Sustainable Investment Research Report" by JLL (Jones Lang LaSalle).
The Nanjing Municipal Investment Promotion Bureau proposed, building on the success of the first two Nanjing Wuxiang ESG Sustainable Investment Salon events, that the organizers leverage the strengths of its guests to continue expanding Nanjing's ESG investment network, gather more green development resources, and inject greater momentum into Nanjing's sustainable development.

Triastek Honored with 2023 Healthcare Application Award at the TCT Awards Ceremony – Triastek’s Melt Extrusion Deposition (MED®) 3D printing technology voted best 3D printing technology in the healthcare sector

Retrieved on:

Thursday, June 8, 2023

Health, Additive, TCT, 3D printing, FDA, Software, Health care

("Triastek"), a global healthcare company developing medicines with proprietary, pioneering 3D printing technology, today announced they have won the 2023 TCT Award for Best 3D Printed Technology in Healthcare, making it the first pharmaceutical company winning this award.

Key Points:

("Triastek"), a global healthcare company developing medicines with proprietary, pioneering 3D printing technology, today announced they have won the 2023 TCT Award for Best 3D Printed Technology in Healthcare, making it the first pharmaceutical company winning this award.
There were 140 entries across the globe submitted for the awards.
The TCT Awards is an annual celebration of outstanding innovations and applications of 3D printing and Additive Manufacturing technologies from across the globe.
Our commitment to innovative endeavors remains steadfast as we strive to advance the industry towards digital product development and intelligent manufacturing.”

China Cancer Antibodies Market Trends & Clinical Trials Insight Report 2023: Clinical Trials Insight By Phase, Indication, Location, Companies, Licensee, Mono/Combination Therapy Approach - ResearchAndMarkets.com

Retrieved on:

Monday, June 5, 2023

The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
The current antibodies pipeline in China is still in the expansion phase as both domestic and international drug developers are continuously foraying into the market.
At present, multiple cancers are dominating the antibody clinical trials landscape in China similar to other developed pharmaceutical markets.
Clinical Trials Insight By Phase, Indication, Location, Companies, Licensee, Mono/Combination Therapy Approach